Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

792 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues.
Lovinfosse P, Rousseau C, Pierga JY, Bouchet F, Cochet A, Alberini JL, Girault S, Vera P, Olivier P, Uwer L, Cachin F, Scarwell B, Lemonnier J, Fourme E, Mesleard C, Martin AL, Lacœuille F, Couturier OF. Lovinfosse P, et al. Among authors: rousseau c. EJNMMI Res. 2019 Dec 12;9(1):109. doi: 10.1186/s13550-019-0579-5. EJNMMI Res. 2019. PMID: 31832803 Free PMC article.
The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).
Palie O, Michel P, Ménard JF, Rousseau C, Rio E, Bridji B, Benyoucef A, Meyer ME, Jalali K, Bardet S, M'vondo CM, Olivier P, Faure G, Itti E, Diana C, Houzard C, Mornex F, Di Fiore F, Vera P. Palie O, et al. Among authors: rousseau c. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1345-55. doi: 10.1007/s00259-013-2450-7. Epub 2013 May 29. Eur J Nucl Med Mol Imaging. 2013. PMID: 23715903 Clinical Trial.
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).
Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, Meyer ME, Jalali K, Bardet S, Lerouge D, Houzard C, Mornex F, Olivier P, Faure G, Rousseau C, Mahé MA, Gomez P, Brenot-Rossi I, Salem N, Dubray B. Vera P, et al. Among authors: rousseau c. Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1057-65. doi: 10.1007/s00259-014-2687-9. Epub 2014 Feb 22. Eur J Nucl Med Mol Imaging. 2014. PMID: 24562641 Clinical Trial.
Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors.
Jamet B, Carlier T, Campion L, Bompas E, Girault S, Borrely F, Ferrer L, Rousseau M, Venel Y, Kraeber-Bodéré F, Rousseau C. Jamet B, et al. Among authors: rousseau c, rousseau m. Oncotarget. 2017 Aug 18;8(44):77050-77060. doi: 10.18632/oncotarget.20335. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100369 Free PMC article.
18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
Gillebert Q, Huchet V, Rousseau C, Cochet A, Olivier P, Courbon F, Gontier E, Nataf V, Balogova S, Talbot JN; other ICHOROPRO investigators. Gillebert Q, et al. Among authors: rousseau c. PLoS One. 2018 Feb 9;13(2):e0191487. doi: 10.1371/journal.pone.0191487. eCollection 2018. PLoS One. 2018. PMID: 29425221 Free PMC article.
[Update of the recommendations of good clinical practice for the use of PET in oncology].
Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Lucian A, Cachin F. Salaün PY, et al. Among authors: rousseau c. Bull Cancer. 2019 Mar;106(3):262-274. doi: 10.1016/j.bulcan.2019.01.002. Epub 2019 Jan 23. Bull Cancer. 2019. PMID: 30683308 French.
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F. Bodet-Milin C, et al. Among authors: rousseau c. Front Med (Lausanne). 2019 Jun 4;6:124. doi: 10.3389/fmed.2019.00124. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214593 Free PMC article. Review.
Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.
Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, Rousseau C, Garcion E, Lacoeuille F, Hindré F, Valable S, Bernaudin M, Bodet-Milin C, Bourgeois M. Bailly C, et al. Among authors: rousseau c. Front Pharmacol. 2019 Jul 10;10:772. doi: 10.3389/fphar.2019.00772. eCollection 2019. Front Pharmacol. 2019. PMID: 31354487 Free PMC article. Review.
Good clinical practice recommendations for the use of PET/CT in oncology.
Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Luciani A, Cachin F. Salaün PY, et al. Among authors: rousseau c. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50. doi: 10.1007/s00259-019-04553-8. Epub 2019 Oct 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 31637482
792 results